Notorious ex-pharmaceutical executive Martin Shkreli is in trouble again with the Federal Trade Commission and today a convicted fraudster has been banned for life from the pharmaceutical industry for founding his company last year. announced that it did not cooperate with the Commission’s investigation into whether it violated the Known as “drug-like”.
In today’s court filing, the FTC has asked a federal judge in New York to find that Shkreli was insulted for failing to provide the FTC with the required documents and for failing to give an interview. Under a court order barring him from being involved in the pharmaceutical industry for life in 2022, Shkreli would have to provide such information to the FTC, the panel noted.
“Martin Shkreli’s failure to comply with the court order demonstrates a clear disregard for the law,” said Holly Vedova, director of the FTC’s Competition Division, in a press release. “The FTC will not hesitate to deploy the full scope of its powers to enable a comprehensive investigation of potential wrongdoing.”
At the center of the controversy is that Shkreli’s Druglike co-founder has cut his lifetime out of the pharmaceutical industry in response to Shkreli’s infamous move to raise the price of cheap, life-saving anti-parasitic drug Daraprim. whether it violates the ban on , in 2015 he went from $17.50 a tablet to $750 a tablet. U.S. District Judge Dennis Court, whose January 2022 court ruling barred him from participating in the industry, wrote:
Locking individuals out of an industry as a whole and limiting their future ability to make a living in that field is a serious remedy and should only be done with caution when fairness demands it. Shkreli’s egregious, willful, repetitive, prolonged, and ultimately dangerous misconduct warrants the imposition of an injunction of this scope.
The injunction barred Shkreli from “participating in any form in the pharmaceutical industry.”
Still, Shkreli’s new company is head-on in the realm of the pharmaceutical industry. In his press release last year, the company said it would “revolutionize” early-stage drug discovery using a distributed computing network “enabled by Web3 technology.” Overall, the company’s web-based suite is touted as enabling drug developers to perform the development tasks of “target identification, drug design, and tools for building and executing large-scale virtual screening workflows.” it was done.
In a press release, Shkreli said users “are responsible and potentially rewarded for discovering the next breakthrough drug,” adding that the technology “disrupts the economics of the pharmaceutical business,” It will compete with major pharmaceutical companies.
In today’s announcement, the FTC said it had initially sought information about the new company and its compliance with the October life ban, but that Shkreli ignored the agency’s “repeated requests.” The FTC not only asked the court that Shkreli was disrespected, but asked him to order Shkreli to comply with the FTC’s investigation within 21 days of the court’s decision.
The FTC also said in court filings that Shkreli has so far failed to pay the $64.6 million release he was ordered to pay along with his life ban.
